News & Articles

Join thousands of scientists from around the world as they come together online to discuss the hottest topics and latest technology solutions

Panel designed to provide surveillance of ongoing mutations of virus that causes COVID-19

How blood culture diagnostics are enabling accurate pathogen identification, resistance detection, and timely therapy

The test helps save on much-needed testing supplies since it allows for testing for all four viruses with one swab

Phoebe Koh Kang Sheing explains why collaboration with other labs is vital for research and how product reviews help

Focusing on innate immunity opens way for precision medicine approaches to AD

Company expands portfolio of SARS-CoV-2 testing solutions with rapid antigen test benchmarked against gold standard RT-PCR

The testing capacity provided by the Fluidigm system aims to help the university limit the spread of the virus

This highly sensitive, cost effective assay is designed for customers who receive a high volume of food samples daily

With this addition, researchers can more easily screen for small molecule modulators of cGAS

Expanded list of instruments and reagents allows more options for labs running CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay

The collaboration aims to advance the scale-up of hMSC manufacturing for regenerative medicine

Watch this on-demand webinar to learn about an alternative assay that aims to identify virus-neutralizing antibodies in as little as five hours

From immunoassays and ELISAs to multi-mode microplate readers, discover the technologies making a difference for other scientists in your field

In a 17-4 vote, the FDA vaccine advisory committee recommended that Pfizer/BioNTech’s COVID-19 vaccine should be distributed to the U.S.

The assay is developed for use in detection, characterisation, and monitoring of the SARS-CoV-2 virus

Access SARS-CoV-2 IgG II test is a semi-quantitative assay that measures patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection

Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide

The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post symptom onset and post positive PCR

Underscores importance of serological testing using the S1 subunit for worldwide seroprevalence and vaccine development